Survival for the fittest: guadecitabine in rel/ref AML

Blood Adv. 2024 Apr 23;8(8):2018-2019. doi: 10.1182/bloodadvances.2024012569.

Authors

Joshua Sheehy^{1

2

3}, Steven W Lane^{1

2

3}

Affiliations

¹ Cancer Care Services, Royal Brisbane and Women's Hospital, Queensland, Brisbane, Australia.
² School of Medicine, University of Queensland, Brisbane, Australia.
³ Cancer Research Program, QIMR Berghofer Medical Research Institute, Queensland, Brisbane, Australia.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antimetabolites, Antineoplastic / pharmacology
Antimetabolites, Antineoplastic / therapeutic use
Azacitidine* / analogs & derivatives*
Azacitidine* / therapeutic use
Female
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / mortality
Male
Middle Aged

Substances

guadecitabine
Azacitidine
Antimetabolites, Antineoplastic